Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET-CD: Guselkumab and Golimumab Combination Therapy in Moderately to Severely Active Crohn's Disease
jRCT2031220309Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of guselkumab, golimumab and guselkumab + golimumab in Crohn's disease (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of participants with clinical remission at Week 48 and Percentage of participants with endoscopic response at Week 48. Started Nov 2022; status: active, not recruiting.
02
Drugs
guselkumabgolimumabguselkumab + golimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031220309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220309.